Back to top
more

Merck & Co. (MRK)

(Delayed Data from NYSE)

$108.70 USD

108.70
9,520,162

-1.05 (-0.96%)

Updated Oct 18, 2024 04:00 PM ET

After-Market: $108.75 +0.05 (0.05%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value C Growth C Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 14% (34 out of 250)

Industry: Large Cap Pharmaceuticals

Better trading starts here.

Zacks News

Merck (MRK) Q4 Earnings & Sales Miss, CEO Frazier Steps Down

Merck (MRK) misses Q4 estimates for earnings and sales. CEO Kenneth C. Frazier, to retire.

Ligand (LGND) Q4 Earnings & Sales Top, 2021 Guidance Raised

Ligand (LGND) reports better-than-expected fourth-quarter 2020 numbers. The company raises outlook for 2021.

Will Merck (MRK) Keep the Earnings Streak Alive in Q4?

Investor focus is likely to be on the sales numbers of Merck's (MRK) blockbuster oncology medicine, Keytruda.

What's in the Cards for Bristol-Myers' (BMY) Q4 Earnings?

Investors will focus on regular top and bottom-line numbers along with key pipeline updates when Bristol-Myers (BMY) reports fourth-quarter 2020 results.

Pfizer's (PFE) Key Brands Likely to Drive Its Q4 Earnings

Pfizer's (PFE) Biopharma unit becomes the "New Pfizer" following the separation of the Upjohn unit. The Q4 announcement will the first quarterly result for the "New Pfizer".

Will Recovery in AbbVie's (ABBV) Earnings Continue in Q4?

Recovery in AbbVie's (ABBV) revenues is likely to have continued in the fourth quarter. Investors focus is likely to be on 2021 guidance when the company reports results in the wake of rising cases.

Kinjel Shah headshot

Pharma Stock Roundup: JNJ, NVS Q4 Earnings, MRK & LLY's Coronavirus Updates

J&J (JNJ) and Novartis (NVS) announce Q4 results. Merck (MRK), AbbVie (ABBV) & Pfizer (PFE) get EU approvals.

Will Glaxo (GSK) Q4 Earnings Recover From Coronavirus Woes?

Glaxo's (GSK) new and specialty products are likely to have driven fourth-quarter sales. The results will provide clarity on the impact of coronavirus on the company's vaccine business.

Eli Lilly (LLY) Q4 Earnings Top, COVID-19 Antibody Boosts Sales

Lilly (LLY) beats fourth-quarter estimates for both earnings and sales. Stock up in pre-market trading.

Merck (MRK) Outpaces Stock Market Gains: What You Should Know

In the latest trading session, Merck (MRK) closed at $77.92, marking a +1.1% move from the previous day.

5 Big Pharma/Biotech Stocks Set to Trump Q4 Earnings Estimates

Let us take a look at some drug/biotech stocks including Sanofi (SNY) and Merck (MRK) that are poised to beat fourth-quarter earnings estimates.

Tirthankar Chakraborty headshot

Wall Street Just Got Hammered: Grab 5 Ultra-Safe Stocks Now

With Wall Street seeing its worst one-day selloff on Jan 27 since October 2020 and with the bearish trend likely to continue, it's safe to bet on stocks like Allete (ALE), B&G Foods (BGS) and Merck (MRK).

Novartis (NVS) Misses on Q4 Earnings, Issues Grim 2021 Outlook

Novartis (NVS) reports dismal fourth-quarter results as the pandemic affected sales. The outlook for 2021 also indicates challenges ahead.

Merck's (MRK) Keytruda Gets EC Nod for MSI-H Colorectal Cancer

The European Commission approves Merck's (MRK) Keytruda as a monotherapy for first-line treatment of patients with metastatic MSI-H or dMMR colorectal cancer.

Pfizer (PFE) to Report Q4 Earnings: What's in the Cards?

Higher sales of Pfizer's (PFE) key brands, Eliquis, Ibrance and Inlyta, and revenues from COVID-19 vaccine are likely to have driven sales in the fourth quarter.

J&J (JNJ) Q4 Earnings & Sales Beat, 2021 Guidance Upbeat

J&J (JNJ) beats fourth-quarter 2020 estimates for both earnings and sales. It issues its adjusted earnings and sales outlook for 2021. Stock up.

Pfizer's (PFE) Bavencio Gets EU Nod for First-Line Bladder Cancer

The European Commission approves Pfizer (PFE) and Merck KGaA's Bavencio as a monotherapy for first-line maintenance treatment in advanced/metastatic urothelial carcinoma.

Bayer (BAYRY) Gets a Boost With Product Approvals and Deals

Bayer (BAYRY) gets a boost as it wins approvals for a few candidates and enters into collaboration agreements.

Will Eli Lilly (LLY) Beat Estimates This Earnings Season?

Higher demand for its growth drugs is likely to have offset generic competition for several other drugs to boost Lilly's (LLY) fourth-quarter sales.

Exelixis (EXEL) Wins FDA Nod for Cabometyx + Opdivo in RCC

Exelixis (EXEL) obtains FDA approval for Cabometyx in combination with immuno-oncology drug, Opdivo, for the first-line treatment of patients with advanced kidney cancer.

Merck (MRK) Stock Moves -0.25%: What You Should Know

Merck (MRK) closed the most recent trading day at $80.98, moving -0.25% from the previous trading session.

Urmimala Biswas headshot

5 Finest PEG Stocks for GARP Investors

Here are five picks out of 45 top-ranked stocks with discounted PEG.

Kinjel Shah headshot

Pharma Stock Roundup: FDA Nod to MRK, AZN, JNJ, GSK Drugs, LLY's New Antibody Deal

Merck (MRK), Glaxo (GSK), AstraZeneca (AZN) and J&J (JNJ) announce FDA approvals.

Bristol Myers' (BMY) Opdivo Label Expansion Gets Priority Review

Bristol Myers' (BMY) sBLA for the label expansion of Opdivo for gastric cancer, gastroesophageal junction cancer or esophageal adenocarcinoma gets priority review.

Merck's (MRK) Heart Failure Drug Vericiguat Gets FDA Nod

Merck (MRK)/Bayer's (BAYRY) vericiguat gets FDA approval for symptomatic chronic heart failure and reduced ejection fraction